Table 2.

Association between pelvic radiation and disease-specific-related patient-reported functional outcomes.

Time	N	Pelvic Radiation, median (quartiles)	No Pelvic Radiation, median (quartiles)	Combined, median (quartiles)	Crude P-valuea	Multivariable adjusted modelb
						Pelvic Radiation vs. No Pelvic Radiation
						Effect estimate (95% CI)	P-value
EPIC-26 urinary incontinence domain score
Baseline	560	93 (73, 100)	100 (79, 100)	100 (79, 100)	0.04	n/a
6 month	570	92 (67, 100)	100 (77, 100)	100 (73, 100)	0.08	0.55 (−3.83 to 4.93)	0.81
1 year	522	92 (71, 100)	100 (79, 100)	100 (75, 100)	0.28	1.78 (−1.85 to 5.42)	0.34
3 year	458	100 (75, 100)	94 (75, 100)	94 (75, 100)	0.95	4.12 (−0.32 to 8.57)	0.07
5 year	402	100 (73, 100)	100 (75, 100)	100 (73, 100)	0.99	3.78 (−1.80 to 9.36)	0.18
EPIC-26 urinary irritative domain score
Baseline	560	88 (69, 94)	88 (75, 94)	88 (75, 94)	0.83	n/a
6 month	564	88 (75, 94)	88 (75, 94)	88 (75, 94)	0.32	0.59 (−2.70 to 3.87)	0.73
1 year	540	88 (81, 98)	88 (77, 94)	88 (80, 94)	0.82	1.74 (−0.86 to 4.34)	0.19
3 year	458	88 (81, 100)	88 (81, 100)	88 (81, 100)	0.26	3.20 (0.01 to 6.39)	0.05
5 year	403	94 (81, 100)	88 (81, 100)	88 (81, 100)	0.99	1.41 (−2.50 to 5.32)	0.48
EPIC-26 bowel function score
Baseline	572	100 (88, 100)	100 (92, 100)	100 (92, 100)	0.24	n/a
6 month	570	100 (79, 100)	96 (83, 100)	96 (83, 100)	0.68	0.94 (−2.60 to 4.49)	0.60
1 year	549	96 (83, 100)	96 (83, 100)	96 (83, 100)	0.78	2.02 (−0.75 to 4.79)	0.15
3 year	469	96 (84, 100)	96 (83, 100)	96 (83, 100)	0.54	3.07 (−0.38 to 6.52)	0.081
5 year	409	96 (83, 100)	96 (88, 100)	96 (88, 100)	0.65	0.76 (−3.38 to 4.90)	0.72
EPIC-26 sexual function score
Baseline	548	48 (12, 80)	58 (22, 80)	58 (18, 80)	0.09	n/a
6 month	535	5 (0, 38)	35 (0, 68)	27 (0, 67)	<0.001	−1.78 (−7.60 to 4.03)	0.55
1 year	529	7 (0, 58)	38 (10, 65)	33 (7, 65)	<0.001	−1.71 (−7.59 to 4.16)	0.57
3 year	448	8 (0, 57)	38 (10, 70)	33 (7, 70)	<0.001	−0.23 (−7.63 to 7.16)	0.95
5 year	384	16 (0, 52)	32 (7, 66)	28 (5, 65)	0.01	2.50 (−5.84 to 10.83)	0.56
EPIC-26 hormonal domain score
Baseline	553	90 (75, 100)	90 (80, 100)	90 (80, 100)	0.06	n/a
6 month	555	80 (65, 90)	90 (75, 100)	85 (75, 100)	<0.001	−0.36 (−4.03 to 3.32)	0.85
1 year	534	85 (70, 95)	90 (75, 100)	90 (75, 100)	0.06	1.41 (−1.82 to 4.65)	0.39
3 year	455	90 (75, 95)	95 (80, 100)	94 (80, 100)	0.12	4.74 (1.22 to 8.27)	0.01
5 year	398	90 (80, 95)	95 (80, 100)	95 (80, 100)	0.16	4.18 (0.40 to 7.97)	0.03

^aCrude P-values are calculated by Wilcoxon test.

^bAll regression models are adjusted for baseline domain score, time since treatment, biopsy Gleason score, PSA at diagnosis (corrected) and propensity scores.